Oxford, UK – 12 November 2015. Oxford Gene Technology (OGT), The Molecular Genetics Company, has entered into a deal with Baylor Miraca Genetics Laboratories (BMGL), licensing the use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology. This novel technology overcomes the limitations of restriction enzyme-based SNP probe approaches previously employed at BMGL for loss of heterozygosity (LOH) detection, allowing accurate array-based analysis of low-input DNA samples.
Based in Texas (US), BMGL provides the highest-quality genomic services across the US and to over 16 countries worldwide, and as part of this objective, utilise aCGH arrays containing both copy number variation (CNV) and SNP probes to identify a broad range of genetic syndromes. For BMGL, OGT’s intensity-based SNP probe technology provides a superior alternative to restriction enzyme-based approaches, which are unable to accurately analyse small amounts of DNA. The probes designed by OGT target each SNP allele, with the intensity ratio following hybridisation allowing reliable detection of LOH. To ensure robust and high-resolution LOH analysis, each probe set has undergone extensive optimisation and validation.
Vice President of Operations at BMGL, Mr. Sean Kim, commented: “We are dedicated to the rapid delivery of the most accurate genetic analyses. Through the application of OGT’s technology, we are now able to provide reliable array-based analysis of both copy number variation and loss of heterozygosity for challenging samples. We are now also looking to other areas of genetic analysis, expanding the use of this technology toward our complete portfolio.”
OGT’s SNP probe technology is a key component of its extensive range of aCGH arrays covering multiple application areas, including cancer and constitutional research. The latest product in development utilising this technology is the CytoSure Constitutional v3 +SNP array, which provides enhanced exon-level coverage of all developmental disorders. As a fully comprehensive approach to its genetic analysis strategy, BMGL also utilises OGT’s Cytocell FISH probes, and following a significant and successful validation programme, plans to further extend the use of these probes. Dr Mike Evans, CEO of OGT commented: “Through granting the licence, we are proud to be advancing the capabilities of such a prominent organisation as the BMGL with our SNP array probe technology and Cytocell FISH probes. This presents just the first step in an ongoing relationship, and we look forward to continuing this close cooperation.”
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech
Notes for editors:
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
For more information on the Company, please visit our website at www.ogt.com
CytoSure™, SureSeq™ and myProbes®: For Research Use Only; Not for Use in Diagnostic Procedures.
Cytocell®: Some products may not be available in the US.
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Help employers find you! Check out all the jobs and post your resume.
